This article first appeared on GuruFocus .
-
Total Revenue:$152.9 million, down 11% year-over-year from $172.1 million.
-
Behavioral Subscription Revenue:$113.9 million, down 22% year-over-year.
-
Clinical Subscription Revenue:$38 million, up 48% year-over-year; ~25% of total revenue vs. 15% a year ago.
-
Adjusted Gross Margin:74.6%, highest level of 2026.
-
Net Income:$15.1 million positive; first two consecutive quarters of positive net income since emergence.
-
Adjusted EBITDA:$51.7 million, up 21% year-over-year; margin of 33.8% vs. 24.9% in Q3 2025.
-
Operating Cash Flow:$32.3 million generated in the quarter.
-
Cash and Cash Equivalents:$126.4 million at quarter end, up ~$25 million from end of June.
-
Total Debt:$423.6 million, reduced more than 70% from ~$1.6 billion following June 2025 reorganization.
-
Marketing Expense:$33.1 million, or 21.6% of revenue, vs. $48.4 million (28.1%) a year ago.
-
Product Development Expense:$5.2 million, or 3.4% of revenue, vs. 4.4% a year ago.
-
Adjusted SG&A Expense:~$25 million, or 16.4% of revenue, down from 17.8%.
-
Total Subscribers:~2.3 million at quarter end.
-
Behavioral Subscribers:~2.1 million, down 26% year-over-year, decline concentrated in Core tier.
-
Core+ Subscribers:546,000, up 16% year-over-year; fourth consecutive quarter of sequential growth; nearly a quarter of total subscribers vs. 16% a year ago.
-
Clinical Subscribers:174,000, up 40% year-over-year, down from 197,000 at end of June.
-
ARPU:$21 monthly subscription revenue per average subscriber, up 14% year-over-year; Core+ ~2x Core ARPU; clinical ARPU $68 (~5x Core).
-
FY2026 Revenue Guidance:Narrowed to $625 million$630 million (prior $620 million$635 million).
-
FY2026 Adjusted EBITDA Guidance:Narrowed to $110 million$115 million (prior $105 million$115 million).
-
FY2026 Adjusted Gross Margin Guidance:~74% (prior above 72%).
-
FY2026 Clinical Revenue Mix:~25% of full-year revenue vs. ~16% in 2025.
-
FY2026 Interest Costs:Projected ~$45 million$50 million; positive operating cash flow expected for full year.
Release Date: November 05, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Clinical subscription revenue increased 48% year-over-year, the largest increase of any quarter in 2026.
-
Core+ subscribers grew sequentially for the fourth consecutive quarter, a milestone not achieved in 20 years.
-
Adjusted EBITDA rose 21% to $51.7 million with a 33.8% margin, up from 24.9% in Q3 2025.
-
Generated positive operating cash flow of $32.3 million and positive net income of $15.1 million.
-
Total debt reduced by over 70% from approximately $1.6 billion to $423.6 million following financial reorganization.
Negative Points
-
Total revenue declined 11% year-over-year to $152.9 million, driven by a 22% drop in behavioral subscription revenue.
-
Behavioral subscribers fell 26% year-over-year to approximately 2.1 million, with declines concentrated in the Core tier.
-
Clinical subscribers declined sequentially from 197,000 to 174,000, reflecting the lapping of 12-month plans and marketing recalibration.
-
Full-year revenue guidance narrowed to $625-$630 million, implying continued top-line pressure.
-
Marketing efficiency gains may not be fully sustainable as the company plans to increase marketing spend in Q4 and beyond.
Q & A Highlights
Q: Alex Fuhrman (Lucid Capital Markets) asked what is driving the sustained turnaround in Core+ now four consecutive quarters of growth and whether the growth in the GLP-1 companion offering comes largely from members obtaining medication outside the Weight Watchers platform. A: CFO Felicia DellaFortuna said it is "all of the above": adoption of the GLP-1 Success program has more than doubled since the start of the year, 40% more Core+ members participate in virtual experiences, and roughly 20% of Core+ sign-ups come from Core member migration. Core+ subscribers grew about 16% year-over-year. CEO Stephen Bye added that the company's differentiation is support nutrition, behavioral coaching, and in-person and virtual workshops regardless of where members get their medication.
Q: Nathan Feather (Morgan Stanley) asked how much of the Clinical segment's sequential decline reflected lapping the one-year compounded semaglutide plans versus underlying trends, and whether Clinical will now follow Behavioral's Q1-peak seasonality. A: CFO Felicia DellaFortuna said the most material factor was Q3 2026 lapping the 12-month commitment plans introduced in Q3 2025 after the company rolled off compounded semaglutide; Q3 also had the year's lowest marketing spend, and spend was recalibrated across the portfolio. She said it is hard to tell whether Clinical seasonality will mirror Behavioral given the Q1 2026 Wegovy pill launch. COO Jonathan Volkmann added that the company is refining clinical intake to better match patients to the right pathway and improve cost transparency earlier in the process.
Q: Owen Rickert (Northland Capital Markets) asked how much of the Q3 EBITDA beat was timing such as lower marketing pulled forward versus durable structural improvement. A: CFO Felicia DellaFortuna attributed the beat to changes in cost execution across cost of sales, product and tech, and adjusted SG&A, which is why the company narrowed its adjusted EBITDA guidance toward the high end of the prior range. She noted marketing spend will step up from Q3 to Q4 ahead of the 2027 peak season.
Q: Justin Ages (CJS Securities) asked about the cash sweep mechanics and priorities for using cash, including whether debt paydown comes first. A: CFO Felicia DellaFortuna said the cash sweep is calculated on the last 10 days of the first quarter and paid on the anniversary of the June 2025 financial reorganization. She said the company has been deliberate in timing and allocating capital, was opportunistic on debt last quarter, and will continue to evaluate further debt paydown or investment as it works through 2027 planning.
Q: Justin Ages (CJS Securities) asked for feedback on the new app and whether it is driving stickier subscribers, plus an update on initiatives such as the menopause offering. A: CEO Stephen Bye said the focus is enhancing the depth of support and value across the member journey, including bringing in-person community experiences into virtual environments and adding new features. CFO Felicia DellaFortuna said the company up-leveled structured behavioral support this year, with the GLP-1 Success program and the menopause offering both included in Core+ and contributing to Core+ growth.
Q: Nathan Feather (Morgan Stanley) asked where new CEO Stephen Bye sees the biggest opportunities to drive growth and improve costs, and what his early priorities are heading into peak season. A: CEO Stephen Bye said the team's passion and member feedback stood out, noting the company touched almost 1.5 million members through virtual and in-person workshops over the last eight weeks. He sees GLP-1 medications expanding the addressable market and views support as the key differentiator, with a focus on bringing focus, execution, and operating and fiscal discipline to return the business to sustainable profitable growth in 2027.
Q: Alex Fuhrman (Lucid Capital Markets) asked whether gross margin pressure from the growing clinical mix is being offset by Core+ growth, given the raised full-year gross margin target. A: CFO Felicia DellaFortuna credited COO Jon Volkmann's team for more efficient cost execution without cutting services. She said full-year adjusted gross margin is now expected at approximately 74%, roughly flat year-over-year, even as Med+ rises from about 15% of revenue in 2025 to about 25% in 2026 and Core+ grows from about 18% to nearly 25% of subscribers. CEO Stephen Bye added that operating discipline and technology will support profitable scaling.
Q: Owen Rickert (Northland Capital Markets) asked for early color on recent partnership announcements, including Google Health, Sam's Club, and LillyDirect. A: CEO Stephen Bye said it is too early to comment on specific metrics for any one partnership but emphasized their importance in meeting members through the most effective channels and optimizing marketing return on investment. He said the company is exploring additional partnerships and will provide updates as progress is made.
Q: Justin Ages (CJS Securities) asked about the Medicare GLP-1 Bridge Program and how Weight Watchers plans to capture the opportunity. A: COO Jonathan Volkmann said the program opens coverage to a substantial population the company is uniquely equipped to serve through both clinical and behavioral infrastructure via Med+ for prior authorizations, coverage, and direct prescribing, or Core+ with the GLP-1 Success Program for outside prescriptions. He noted industry data indicates most interest comes from people new to GLP-1s, confirming the program expands the overall market, and said the focus is on expanding awareness among eligible seniors.
Q: Alex Fuhrman (Lucid Capital Markets) asked about the sustainability of Core+ growth and whether it reflects converting stickier Behavioral members to the higher-priced offering or new members entering at the ~$20/month tier rather than the ~$10 tier. A: CEO Stephen Bye pointed to the brand and support proposition across Core+, Med+, and clinical care as the foundation. CFO Felicia DellaFortuna said growth is driven by GLP-1 Success program adoption, more virtual participation, and member migration, with about 20% of Core+ sign-ups coming from Core members, and noted Core+ subscriber growth accelerated through the year to approximately 16%.
Q: Nathan Feather (Morgan Stanley) asked whether Clinical's Q2-to-Q3 decline was driven by the lapping of one-year compounded
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
